Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

All-trans retinoic acid and RARβ agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MXMiao XianQYQing Yi

Discussion

Loading...

Member takes

Overview

Research demonstrates enhanced IMiD sensitivity in high-risk t(4;14) multiple myeloma with RARβ agonists, suggesting a novel therapeutic strategy.

Key Points

  • To investigate the efficacy of all-trans retinoic acid and RARβ agonists on IMiD-based treatments for t(4;14) multiple myeloma.
  • Conducted in vitro experiments on t(4;14) MM cell lines using ATRA and RARβ agonists.
  • Used CRISPR/Cas9 to generate RARβ knockout MM cell lines for analysis of treatment efficacy.
  • Analyzed chromatin changes and signaling pathways involved with ATAC-seq and RNA-seq methods.
  • ATRA and RARβ agonists enhanced the sensitivity of t(4;14) MM cells to IMiDs.
  • RARβ-KO cells showed reduced apoptosis with ATRA and pomalidomide compared to controls.
  • Combination treatment reduced FGFR3 expression and targeted the PI3K/AKT signaling pathway, increasing MM cell death.

Cite This Study

Xian et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d133https://doi.org/10.1182/blood-2025-5817
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Activating RARβ to overcome immunomodulatory drug resistance in t(4;14) human myeloma2026
  2. 2Super-enhancer-mediated regulation of CD38 inducibility in multiple myeloma via the MAF/TRIM47/RARα axis2025
  3. 3Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies2026
  4. 4Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death2025
  5. 5Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression2026 · 1 citations